Clinical trials: Glomerulonephritis
IgA Nephropathy (IgAN)
Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
- Trial name
- NCT06670352
- Testing
- HSK39297 50mgBID, HSK39297 100mgBID, HSK39297 200mgQD
- Where
- 2 sites in China
- Volunteers
- 87 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
IgA Nephropathy
Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis
The purpose of this study is to: 1. To evaluate the latest effects of TW for IgA nephropathy (IgAN) with asymptomatic abnormal urinalysis. 2. To evaluate the safety and tolerability of TW.
- Trial name
- NCT00885547
- Testing
- tripterygium wilfordii (TW)
- Volunteers
- 90 people
- Sponsor
- Nanjing University School of Medicine
Lupus Nephritis, Systemic Lupus Erythematosus
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
The purpose of the study is to evaluate the safety and preliminary efficacy of ATA3219 for treatment of participants with lupus nephritis (LN) following lymphodepletion (LD) and in participants with extrarenal systemic lupus…
- Trial name
- NCT06429800
- Testing
- ATA3219
- Where
- United States
- Sponsor
- Atara Biotherapeutics
Lupus Nephritis
Comparison between2 Drugs in Lupus Nephritis
The aim of this work is to study the effect and side effects of the cyclophosphamide versus mycophenolate in lupus nephritis
- Trial name
- NCT04424602
- Testing
- cyclo phosphamide, mycophenolate
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University
Glomerulonephritis, Proteinuria
Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
-Evaluate the efficacy and safety of Shenyankangfu Tablets to control the proteinuria of patients with primary glomerulonephritis compare with Losartan potassium.
- Trial name
- NCT02063100
- Testing
- Shenyankangfu tablets, Losartan potassium 50mg, Shenyankangfu tablets and Losartan potassium 50mg
- Where
- 43 sites in China
- Volunteers
- 720 people
- Sponsor
- Chinese PLA General Hospital
Lupus Nephritis
Universal CAR-T Cell Therapy for Refractory Lupus Nephritis
This investigator-initiated trial aims to assess the efficacy and safety of combination therapy using universal CAR-T cells targeting BCMA and CD19 in refractory lupus nephritis.
- Trial name
- NCT06681337
- Testing
- BCMA CART + CD19 CART
- Volunteers
- 10 people
- Sponsor
- Bioray Laboratories
Vascular Access Complication, Apheresis Related Complication
Vascular Access Complications for Therapeutic Apheresis in Nephrology
The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.
- Trial name
- VACTANE (NCT05894317)
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Glomerulonephritis
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of KP104 in participants with IgAN and C3G. The study will start with enrolling the IgAN cohort.
- Trial name
- NCT05517980
- Testing
- KP104
- Volunteers
- 52 people
- Sponsor
- Kira Pharmacenticals (US), LLC.
IgA Nephropathy
A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants
The goal of this clinical trial is to evaluate the effect of food (a high-fat, high-calorie meal) on the PK of a single oral dose of budesonide delayed release tablet in healthy participants.
- Trial name
- NCT07897240
- Testing
- Budesonide delayed release tablet
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Triastek, lnc.
IgA Nephropathy
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
Efficacy and safety of LNP023 in IgAN patients
- Trial name
- NCT03373461
- Testing
- LNP023
- Where
- 56 sites in Argentina, Australia and 23 more
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Focal Segmental Glomerulosclerosis, Proteinuria
ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank
Nephrotic syndrome is the clinical phenotype of a heterogeneous group of glomerular diseases that may present with varying degrees of urinary protein loss (proteinuria), dysproteinemia in the blood, fluid retention and impaired…
- Conditions
- Focal Segmental Glomerulosclerosis, Proteinuria, Nephrotic Syndrome, Nephrotic Syndrome Steroid-Resistant
- Trial name
- NCT06162546
- Testing
- Registry
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Christoph Aufricht
Membranous Nephropathy
An Outcome Analysis of Primary Membranous Nephropathy
This is an observational study intended to track the course of the primary membranous nephropathy disease in real-world clinical practice.
- Trial name
- PROMENADE (NCT06242327)
- Where
- 2 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Lupus Nephritis
ACTHar in the Treatment of Lupus Nephritis
Systemic Lupus Erythematosus (SLE) is a disease in which the immune system attacks the healthy cells and tissues, causing inflammation that can damage organs in the body.
- Trial name
- ACTHar (NCT02226341)
- Testing
- CellCept, ACTHar gel
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Focal Segmental Glomerulosclerosis
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
This study will investigate whether GC1008, an antibody which neutralizes TGF-beta, is safe in treating patients with the disease called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT00464321
- Testing
- GC1008
- Where
- 9 sites in United States, Germany and 2 more
- Volunteers
- 16 people
- Sponsor
- Genzyme, a Sanofi Company
IgA Nephropathy
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in subjects with plasma cell-driven autoimmune diseases
- Trial name
- NCT06774664
- Testing
- SCTC21C
- Where
- 20 sites in China
- Volunteers
- 99 people
- Sponsor
- Sinocelltech Ltd.
IgA Nephropathy (IgAN), Membranous Nephropathy
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
This study is a single-arm, open-label, dose-escalation and dose-expansion clinical trial, divided into two phases: the first phase is the dose-escalation phase, and the second phase is the dose-expansion phase.
- Conditions
- IgA Nephropathy (IgAN), Membranous Nephropathy, ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN), Refractory Podocytopathy
- Trial name
- NCT07389499
- Testing
- CD19-targeted iNKT Cell Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Grit Biotechnology
Systemic Lupus Erythematosus, Lupus Nephritis
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.
- Trial name
- NCT05798117
- Testing
- YTB323
- Where
- 10 sites in Australia, France and 3 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Lupus Nephritis
Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis
The objective of this study is to assess the as efficacy of rituximab as induction therapy in membranous lupus nephritis. Safety and tolerability will additionally be assessed.
- Trial name
- NCT00908986
- Testing
- Rituximab
- Sponsor
- Northwell Health
SLE, LN
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
An Exploratory, Single-Arm, Open-Label, Dose-Escalation Study of the Safety, Tolerability, PK, PD, and Efficacy of Anti-CD19/BCMA Universal CAR-T Therapy RD06-05 in Autoimmune Diseases (including SLE/LN, AAV/AAGN, Anti-GBM, MN…
- Conditions
- SLE, LN, ANCA Associated Vasculitis, ANCA-Associated Glomerulonephritis
- Trial name
- NCT07203404
- Testing
- RD06-05 CART Cell Injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Renal Impairments, IgA Nephropathy (IgAN)
A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment
This is a Phase I trial designed to evaluate the impact of renal impairment on the efficacy and safety of the drug by comparing pharmacokinetic (PK) parameters and pharmacodynamic (PD) markers after a single subcutaneous…
- Trial name
- NCT07445906
- Testing
- RG002C0106
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.